Skip to main content
. 2018 Jan 11;25(5):267–273. doi: 10.1136/ejhpharm-2017-001411

Table 1.

Main characteristics of the 162 patients included in the programme

Mean ± SD  age in years 81.1 ± 6.2
Female, n (%) 86 (53.1)
Care objectives, n (%)
 Post-acute convalescent care 90 (55.6)
 Palliative care 50 (30.9)
Median of hospitalisations in the last year (range) 2 (1–6)
Pathologies
 Median (range) per patient 3 (2–6)
  Hypertension, n (%) 124 (76.5)
  Moderate-severe renal disease, n (%) 87 (53.7)
  Dyslipidaemia, n (%) 84 (51.9)
  Dementia, n (%) 78 (48.1)
  Congestive heart failure, n (%) 71 (43.8)
Comorbidity, n (%)
High
  CCI  ≥ 3 points 126 (77.8)
Very high
  CCI  ≥ 5  points 83 (51.2)
  Age-adjusted CCI  ≥ 5 points 156 (96.3)
Cognitive impairment, n (%)
 Pfeiffer score ≥3 errors 119 (73.5)
Total dependence, n (%)
 Barthel Index ≤20 points 137 (84.6)
Median hospital LOS in days (range) 42.5 (3–160)
In-hospital mortality, n (%) 83 (51.2)
Prescribed medication at admission
 Total number, n 1970*
 Mean±SD per patient 12.2±3.7
  ≥10 medications, n (%) 118 (72.8)
  ≥15 medications, n (%) 43 (26.5)
  ≥20 medications, n (%) 5 (3.1)

CCI Charlson Comorbidity Index, LOS length of stay.

*Total number of admission long-term care hospital medications used to calculate reconciliation error, PIM, PPO and drug interaction rates.

HHS Vulnerability Disclosure